The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Critical roles of inflammation in atherosclerosis
Open accessAbstract
There is accumulating evidence that vascular inflammation plays critical roles in pathophysiology of atherosclerosis. It is widely accepted that both innate and adaptive immune responses are important for initiation and progression of atherosclerosis, which mainly consist of monocytes, macrophages, neutrophils, T lymphocytes, and B lymphocytes. Moreover, inflammatory biomarkers such as high-sensitivity C-reactive protein and interleukin-6 are known to predict future cardiovascular events, as well as conventional low-density or high-density lipoprotein cholesterol. Thus, current understanding of the inflammatory mechanisms of atherosclerosis have led us to explore novel therapeutic approaches that reducing vascular inflammation itself could lower the rates of critical cardiovascular events. To address the inflammatory hypothesis of atherosclerosis, results of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial have been recently reported that anti-inflammatory therapy using canakinumab, a monoclonal antibody targeting interleukin-1β, significantly reduced recurrent cardiovascular events for secondary prevention of myocardial infarction at high inflammatory risk. In this review, we will first outline the mechanisms of atherosclerosis, especially focusing on their inflammatory aspects. Then we will introduce several critical inflammatory biomarkers that contribute to risk stratification of clinical cardiovascular events. Lastly, we will discuss potentiality and future perspectives of reducing inflammation as a novel therapeutic target for atherosclerotic cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,736
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Inflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Ridker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Natural regulatory T cells control the development of atherosclerosis in mice
Ait-Oufella, H., Salomon, B. L., Potteaux, S., Robertson, A.-K. L., Gourdy, P., Zoll, J., Merval, R., Esposito, B., Cohen, J. L., Fisson, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1343 · Cited by 1,100
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Kaptoge, S., Seshasai, S. R. K., Gao, P., Freitag, D. F., Butterworth, A. S., Borglykke, A., Di Angelantonio, E., Gudnason, V., Rumley, A., Lowe, G. D. O., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht367 · Cited by 666
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
Ridker, P. M., Howard, C. P., Walter, V., Everett, B., Libby, P., Hensen, J., & Thuren, T. (2012) · Circulation · doi:10.1161/circulationaha.112.122556 · Cited by 530
Multiple Roles for Neutrophils in Atherosclerosis
Soehnlein, O. (2012) · Circulation Research · doi:10.1161/circresaha.111.257535 · Cited by 498
Inflammation in atherosclerosis
Taleb, S. (2016) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2016.04.002 · Cited by 375
The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1
Dinarello, C. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431011 · Cited by 373
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
McInnes, I. B., Thompson, L., Giles, J. T., Bathon, J. M., Salmon, J. E., Beaulieu, A. D., Codding, C. E., Carlson, T. H., Delles, C., Lee, J. S., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204345 · Cited by 324
Targeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Vaccine against arteriosclerosis: an update
Chyu, K., Dimayuga, P. C., & Shah, P. K. (2017) · Therapeutic Advances in Vaccines · doi:10.1177/2051013617693753 · Cited by 92
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 86
Kita, T., Yamashita, T., Sasaki, N., Kasahara, K., Sasaki, Y., Yodoi, K., Takeda, M., Nakajima, K., & Hirata, K. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu002 · Cited by 85
Rho, Y. H., Oeser, A. M., Chung, C. P., Milne, G. L., & Stein, C. M. (2009) · Archives of Drug Information · doi:10.1111/j.1753-5174.2009.00019.x · Cited by 84
Multiple potential roles for B cells in atherosclerosis
Sage, A. P., & Mallat, Z. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.900272 · Cited by 48
Bermúdez, V., Rojas, J., & Velasco, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.47 · Cited by 11
Cited by
Role of pyroptosis in cardiovascular disease
Zhaolin, Z., Guohua, L., Shiyuan, W., & Zuo, W. (2019) · Cell Proliferation · doi:10.1111/cpr.12563 · Cited by 493
Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity
Frismantiene, A., Philippova, M., Erne, P., & Resink, T. J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.08.019 · Cited by 406
Lee, S.-G., Lee, S.-J., Lee, J.-J., Kim, J.-S., Lee, O.-H., Kim, C.-K., Kim, D., Lee, Y.-H., Oh, J., Park, S., et al. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2019.0296 · Cited by 75
Metadata
- Authors
- Moriya, J.
- Venue
- Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 73
- Issue
- 1
- Pages
- 22-27
- ISSN
- 0914-5087 (ISSN-L)
- OpenAlex
- W2808192396
- Cited by
- 339
- References
- 31
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.